innovations and know-how in exosome production suited for many clinical applications
TORONTO and HAIFA, Israel, Feb. 20, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, proudly underscores its expanding Intellectual Property (IP) portfolio, which will serve as the foundation for its strategic goal of licensing the innovative ExoTherapy platform to interested biotech companies.
NurExone’s Intellectual property portfolio describes the ExoTherapy platform’s comprehensive technology and processes for the production of nanodrugs including large scale production of exosomes, loading of active molecules and the composition of the exosomes themselves. The loading technology was presented to the public in the press release of February 12, 2024. Today the Company is highlighting its innovative bioreactor and biological processes for:
- High yield repeatable production of exosomes
- Production of natural and potent exosomes (not synthetically engineered)